

FORM PTO	-1449	U.S. DEPARTMENT OF COMMER PATENT AND TRADEMARK OFF			ATTY, DOCKET NO.: OC01128K		SERIAL NO.: 09/768,445			
INF	ORN	MATION DISCLOS	APPLICANT:							
1141	J1 111	BY APPLIC	Houghton, et al.							
(Use several sheets if necessary)					FILING DATE: January 24, 2	GROUP:	GROUP:			
			U.S. P.	ATENT DOCUM			_ 			
*EXAMINER	T	DOCUMENT	DATE	NAM		CLASS	SUB-	FILING	DATE IF	
INITIAL	 	NUMBER	<u> </u>					APPRO		
	AA	<u> </u>			•		Ţ			
	AB		· ·	 		 	<u> </u>	<u> </u>		
	AC AD	1	 				 	 		
	AE	<u> </u>				 	 			
	AF		 			 	 	 	·····	
	AG		 	†		 	+			
	АН			 		 	 	 		
	Al						 	·		
	AJ						†			
	AK									
		F	OREIGN	PATENT DOC	UMENTS					
		DOCUMENT	DATE	COUNTRY		CLASS	SUB-	TRANSI	ATION	
- A-M		NUMBER					CLASS	YES	NO	
(11)	AL	WO 97 07804 A								
	AM				· · · · · · · · · · · · · · · · · · ·					
	AN		 	ļ <u>.</u>		<u> </u>				
	AO					L		L	L	
	OTI	HER DOCUMENT	S (Includ	ing Author, Title	e, Date, Perti	in <u>ent P</u> a	iges, Etc	c.)		
()	AP	Kano, Y., et al., "Effe	ects of CPT-	-11 in Combination	with Other Ant	li-Cancer	Agents in	Culture	H	
(Ww	ÁQ	February 2, 1992, International Journal of Cancer, Vol. 50, No. 4, pgs. 604-610 Eder, JP et al., "Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo", 1998, Cancer Chemother. Pharmacol., Vol. 42, No. 4, pgs. 327-335								
	AR.	Plowman I et al "	Preclinical	Antitumor Activity	. 4, pgs. 327-3	Jo in Mine	. 56			
0.00		Plowman, J., et al., "Preclinical Antitumor Activity of Temozolomide in Mice: Efficacy Against Human Brain Tumor Xenografts and Synergism with 1,3-Bis (2-Chloroethyl)-1- Nitrosurea", 19								
OVII		Cancer Research, Vo	ol. 54, No. 1	14, pgs. 3793-3799	9	_				
\sim	AS	Newlands, E.S., et al., "Temozolomide: A review of its Discovery, Chemical Properties, Pre- Clinical Development and Clinical Trials", 1997, Cancer Treatment Reviews, Vol. 23, No. 1, pgs.								
$O(0)^{\circ}$	1 }	Clinical Development	t and Clinic	al Trials", 1997, Ca	ancer Treatmen	t Review	s, Vol. 23	, No. 1,	pgs.	
	ÆΤ	35-61	II Colo o di ilo					 _		
am	~ '	Vikas J. Patel, et al., "Schedule-dependent Activity of Temozolomide plus CPT-11 against a Human Central Nervous System Tumor-derived Xenograft ¹ ", 2000, Clinical Cancer Research, Vol.								
\(\alpha_1\) \		6, pgs. 4154-4157	ous System	1 Tumor-denved A	anogran , ∠oot	J, Clinicai	Cancer F	(esearci	n, Vol.	
00.0	ρÚ	Peter J. Houghton, e	t al., "Antitu	mor Activity of Ter	nozolomide Co	mbined w	ith Irinote	can is P	artly	
Ollo		Independent of O ⁶ -M Xenograft Models ¹ ", 2	lethylguanin	ne-DNA Methyltran:	sferase and Mi	smatch R	Repair Phe	notypes	in	
EXAMINER		0.04	^	DATE CO	DNSIDERED					
		(/)// /	m			6-10	- 111			
*EVANAINIE). In:	isial if mafarana a security				6-10	-09			
hrough cita	tion i	itial if reference consider from the conformance and the conformance are the conformance and the conformance are the conformance and the conformance are the conforman	perea, wnet	ner or not citation i	s in conforman	ce with M	IPEP 609	, Draw I	ine	
applicant.			2110 1101 0011	Sidered. Include o	opy of this loff	ı wılıı nex	.t commu	ncation	10	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERC				ERCE	ATTY, DOCKE	SERIAL NO.:				
PATENT AND TRADEMARK OFFIC					FFICE	OC01128K 09/767,424				
j∰i' c	RM	ATION DISCLOS BY APPLIC	SURE STA	ATEME	١T	APPLICANT: SARA L. ZAI	KNOEN			
Use several sheets if necessary)					FILING DATE	GROUP:				
	(y)						2, 2001	<u> </u>		
d Samuel RY	<i>-</i>			ATENT						
EXMINER		DOCUMENT	DATE NAME			CLASS		FILING DATE IF APPROPRIATE		
INITAAL		NUMBER	 				100116		APPRO	PRIATE
4/10	AA	6,346,524 B1	02/02		RAG	AB	A61K	31/33		
	AB							<u> </u>		
	AC		ļ	<u> </u>			<u> </u>	<u> </u>	 	
	AD_	· · · · · · · · · · · · · · · · · · ·							├ ──	
	AE		<u> </u>					ļ	L	
	AF					····		 	<u> </u>	
	AG		<u> </u>	<u> </u>						
	AH_								<u> </u>	
	ΑI		<u> </u>					<u> </u>		
	AJ		l				_l			
	AK						l	<u> </u>	<u> </u>	
		-	FORFIGI	N PATFI	NT DOO	UMENTS				
	Γ	DOCUMENT	DATE	COUNT		<u> </u>	CLASS	SUB-	TRANS	LATION
,	1	NUMBER			•		1	CLASS	YES	TNO
	AL	1101110111		+						+
	AM		-}	 					†	†
	AN		 	 					 	+-
	AO			+			 	<u> </u>	 	
	AP			 	*******					
	OT	HER DOCUMEN	TS (Inclu	dina Aut	hor, Titl	e, Date, Per	tinent Pa	iges, Et	c.)	
	AQ	T								
	AR				-					
	AS						·····			
	AT					<u>-</u>				
	AU									
	AV									
EXAMINER		L			DATE C	ONSIDERED				
$\mathcal{C}\mathcal{D}_{\mathcal{A}}$.					6-10-04					
*EVANAINIT	D. 1-	itial if reference cons	sidered wh	other or n	ot citation	is in conform			d. Draw	line
CYMMINE	rc. 11	if not in conformance	sidered, Wil	Culti Of II	or citation		DITOR MILLI	*II LI 00	J, Diaw	